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ABSTRACT Pseudomonas aeruginosa is a common Gram-negative opportunistic
pathogen that is intrinsically resistant to a wide range of antibiotics. The develop-
ment of a broadly protective vaccine against P. aeruginosa remains a major chal-
lenge. Here, we used an attenuated strain of Salmonella enterica serovar Typhimu-
rium as a vehicle to express P. aeruginosa antigens. A fusion between the S. enterica
type III secretion effector protein SseJ and the P. aeruginosa antigen PcrV expressed
under the control of the sseA promoter was translocated by Salmonella into host
cells in vitro and elicited the generation of speciﬁc antibodies in mice. Mice immu-
nized with attenuated Salmonella expressing this fusion had reduced bacterial loads
in the spleens and lungs and lower serum levels of proinﬂammatory cytokines than
control mice after P. aeruginosa infection. Importantly, immunized mice also showed
signiﬁcantly enhanced survival in this model. These results suggest that type III se-
cretion effectors of S. enterica are appropriate carriers in the design of a live vaccine
to prevent infections caused by P. aeruginosa.
IMPORTANCE The Gram-negative bacterium Pseudomonas aeruginosa is an impor-
tant opportunistic pathogen that causes infections in cystic ﬁbrosis and hospitalized
patients. Therapeutic treatments are limited due to the emergence and spread of
new antibiotic-resistant strains. In this context, the development of a vaccine is a
priority. Here, we used an attenuated strain of Salmonella enterica serovar Typhimu-
rium as a vehicle to express and deliver the Pseudomonas antigen PcrV. This vaccine
induced the generation of speciﬁc antibodies in mice and protected them from le-
thal infections with P. aeruginosa. This is an important step toward the development
of an effective vaccine for the prevention of infections caused by P. aeruginosa in
humans.
KEYWORDS PcrV, Pseudomonas aeruginosa, Salmonella-delivered vaccines, SseJ, type
III secretion
Pseudomonas aeruginosa is an environmentally ubiquitous, Gram-negative, oppor-tunistic bacterial pathogen. It is one of the more commonly reported nosocomial
pathogens (1). P. aeruginosa forms bioﬁlms in the upper airways of cystic ﬁbrosis
patients and repeatedly colonizes the lower airways, leading to chronic lung infection
(2). It is also a common pathogen linked to burn wound infections (3), ventilator-
associated pneumonia in intensive care unit patients (4), and urinary infections in
patients with catheters in the upper urinary tract (5). In addition, P. aeruginosa is a
leading cause of life-threatening infections in immunocompromised hosts with under-
lying diseases such as cancer or AIDS (6).
P. aeruginosa is intrinsically resistant to a wide range of antibiotics (7) and possesses
adaptation strategies that facilitate its persistence in the environment, such as bioﬁlm
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formation (8). In addition, the increasing selection of additional acquired resistance
mechanisms, via mutations or horizontal gene transfer, has led to the emergence of
multidrug-resistant strains (9).
In this context, the development of vaccines that limit the spread of P. aeruginosa
infections is a major challenge. This has been the focus of research efforts for almost
half a century, and over the last 25 years, multiple P. aeruginosa vaccines have been
assessed in clinical trials (10). However, with the recent failure of the IC43 vaccine in a
phase II clinical trial (11), there are currently no approved vaccines against P. aeruginosa
or vaccines in advanced stages of clinical development (12). Renewal of the P. aerugi-
nosa vaccine pipeline is thus a high priority.
Many antigens and delivery protocols have been tested as vaccine candidates, but
to increase the efﬁcacy of vaccination, novel approaches are clearly needed. Such
approaches may combine previously tested P. aeruginosa antigens with delivery meth-
ods that were successful for other antigens.
The protective efﬁcacy of outer membrane proteins OprF and OprI have been shown
in animal models and clinical trials (13, 14). Another promising candidate is the P.
aeruginosa V antigen (PcrV), the tip protein of the type III secretion system (T3SS), which
is critical for its assembly and regulation. These secretion systems are present in many
Gram-negative pathogens and symbionts and inject effector proteins into host cells to
interfere with host cellular processes (15). Blockade of PcrV by speciﬁc antibodies
inhibits the translocation of type III effector proteins, and immunization with recom-
binant PcrV or administration of anti-PcrV antibodies can protect animals from lethal P.
aeruginosa infections (16, 17). Killed whole-cell and live attenuated P. aeruginosa
vaccines present multiple antigens to the immune system but may exhibit some
toxicity or residual virulence, whereas the use of recombinant proteins is safer but may
induce a weaker immune response (18).
The use of live attenuated bacterial or viral pathogens is an interesting alternative
for delivering heterologous antigens (19). Salmonella is among the ﬁrst bacteria used
for this purpose and has well-established protocols for genetic manipulation. Addi-
tional advantages of Salmonella-based vaccines are the low cost of production, absence
of animal products, safety, and elicitation of efﬁcient humoral and cellular immune
responses via stimulation of innate and adaptive immunity (20). Salmonella enterica is
a facultative intracellular pathogen that, once inside the host cell, resides in a modiﬁed
phagosome known as the Salmonella-containing vacuole (SCV) (21). S. enterica pos-
sesses two T3SSs, T3SS1 and T3SS2, encoded in Salmonella pathogenicity islands 1
(SPI1) and 2 (SPI2), respectively (22–24). T3SS1 translocates effector proteins through
the host plasma membrane and is required for invasion of nonphagocytic cells. T3SS2
is necessary for intracellular survival and secretes effectors from inside the SCV. Previous
studies have shown that T3SS-mediated translocation can be used for efﬁcient delivery
of heterologous antigens that are fused to effector proteins to the cytosol of antigen-
presenting cells (25–27). In fact, live S. enterica vaccines based on these delivery systems
have been shown to produce protective immunity against other bacterial and viral
pathogens (28–31) and are also being used in the ﬁeld of tumor immunotherapy
(32–36).
The aim of this study was to develop a vaccine against P. aeruginosa using S. enterica
T3SS effectors as carriers for relevant antigens. A strong protective immune response
against the PcrV antigen was obtained using the SseJ effector as a carrier.
RESULTS
Construction and evaluation of Salmonella vectors for delivery of P. aeruginosa
antigens. A previous study showed that the effector SseJ was an appropriate carrier
for inducing a robust immune response against the model antigens ovalbumin and
listeriolysin in vitro and in vivo (25). We used the promoter of the Salmonella SPI2 gene
sseA (PsseA) to direct the expression of fusion proteins containing the Salmonella
effector SseJ as well as Pseudomonas antigens OprF/I and PcrV (Fig. 1A and B and
Materials and Methods). SseJ is secreted through the T3SS2 from inside the SCV (37),
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FIG 1 Generation of protein fusions for delivery of Pseudomonas aeruginosa antigens. (A) Vector
pWSK29 was used for the generation of two plasmids in three steps. In the ﬁrst step, part of the
coding region of antigens OprF/OprI (see Materials and Methods for the generation of the hybrid
gene oprF-oprI) or the complete coding region (without the stop codon) for the antigen PcrV from
P. aeruginosa was ampliﬁed by PCR. DNA encoding the FLAG epitope and recognition sites for BamHI
and NotI endonucleases was added with the primers used for ampliﬁcation. These amplicons were
cleaved with BamHI and NotI and ligated into pWSK29 previously cleaved with the same restriction
enzymes. In the second step, the coding region of sseJ without the stop codon was ampliﬁed by PCR
and ligated to the plasmids obtained in the ﬁrst step previously cleaved with EcoRI and BamHI
restriction enzymes. Finally, the promoter region of sseA (nucleotides 411 to 15 relative to the
translation start site) was ampliﬁed by PCR and added to the plasmids obtained in the second step
previously cleaved with endonucleases KpnI and EcoRI. Numbers in parentheses indicate base pairs
relative to the start of the coding region. (B) Fusion proteins that are expected to be produced under
the appropriate conditions after the introduction of the plasmids described in panel A in S.
Typhimurium. Numbers in parentheses refer to amino acids included in the fusions. Both fusions
include the complete amino acid sequence of SseJ and a C-terminal FLAG epitope to facilitate
identiﬁcation of the fusions by Western blotting. The expected molecular masses are 70.18 kDa for
SseJ-OprF/I-FLAG and 79.23 kDa for SseJ-PcrV-FLAG. (C) Derivatives of S. Typhimurium strain 14028
carrying plasmids encoding OprF/I (Opr) or PcrV fusion proteins were grown in LPM. A FLAG tag was
used for detection of the proteins by immunoblotting. Molecular weights in kDa are indicated on the
left. (D) Salmonella strains that were derivatives of the wild-type strain (wt) or the ssaV mutant
(carrying a nonfunctional T3SS2) expressing SseJ in fusion with Pseudomonas antigens OprF/I (Opr)
or PcrV with a FLAG tag were grown under noninvasive conditions. These bacteria were used to
infect RAW264.7 cells for 8 h. Cells were lysed with 1% Triton X-100 in PBS and centrifuged 15 min
at 15,000  g. The pellets and the ﬁltered concentrated supernatants (cytosol) were analyzed by
immunoblotting with anti-FLAG antibodies to detect translocation of fusion proteins into the host
cytosols. Incubations with anti-DnaK or anti-GroEL antibodies were used as controls of contamina-
tion of the cytosol fraction with nonsecreted bacterial proteins. (E) Expression of the fusion proteins
SseJ-OprF/I (Opr) and SseJ-PcrV (PcrV) was analyzed in an aroA aroB (aro) background. Bacteria were
grown in LPM (left) or were grown for 24 h at 37°C with shaking in LB medium and used to infect
RAW264.7 macrophages (right). Protein extracts were analyzed by immunoblotting with an anti-
FLAG antibody.
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and PsseA responds to intravacuolar signals and is induced several hours after invasion
(38, 39). The constructs were prepared using the low-copy-number plasmid pWSK29 as
the vector. S. enterica serovar Typhimurium strain 14028 containing the plasmids with
the hybrid genes was grown in low-magnesium minimal medium (LPM), a medium that
imitates intravacuolar conditions, and the expression of fusion proteins was monitored
by Western blotting against the FLAG tag that was also added. The results shown in
Fig. 1C indicate that both plasmids yielded signiﬁcant levels of protein production.
Strains containing these plasmids were tested for their capacity to translocate the
fusion proteins into RAW264.7 macrophages. Translocation was detected for both
fusions, SseJ-OprF/I-FLAG and SseJ-PcrV-FLAG, by Western blotting using an anti-FLAG
antibody (Fig. 1D). Translocation was T3SS2 dependent, since it was not observed in an
ssaV mutant background (SsaV is an essential component of T3SS2).
Antibody responses induced by candidate vaccines against P. aeruginosa. The
plasmids generated as described above were introduced into an attenuated strain of S.
Typhimurium with mutations in aroA and aroB. Expression of the fusion proteins was
detected again in this background, both in LPM (imitating intravacuolar conditions) and
during infection of macrophages (Fig. 1E), and C57BL/6 mice were immunized by
intraperitoneal injections with the attenuated strains carrying the plasmids. Mice
immunized with Salmonella aroA aroB without pWSK29 derivatives were used as the
controls. Indirect enzyme-linked immunosorbent assays (ELISAs) were performed using
sera collected 21 days after immunization. As shown in Fig. 2, immunization with
Salmonella expressing SseJ-PcrV elicited detectable levels of antigen-speciﬁc total IgG
in all mice, whereas Salmonella expressing SseJ-OprF/I was not able to induce a speciﬁc
response. As expected, control mice had no detectable antigen-speciﬁc IgG.
Protective responses induced by candidate vaccines. Vaccine efﬁcacy was tested
by infecting immunized and control mice with P. aeruginosa strain PAO1 by intraperi-
toneal injections, and survival was monitored over 7 days. As shown in Fig. 3, most of
the mice vaccinated with Salmonella expressing the SseJ-PcrV construct survived the
challenge, whereas mice vaccinated with Salmonella expressing SseJ-OprF/I or control
Salmonella were not signiﬁcantly protected. Statistical analysis of these survival data
showed signiﬁcant protection for the group vaccinated with Salmonella expressing
SseJ-PcrV, whereas there was no signiﬁcant difference between the control group and
the group vaccinated with Salmonella expressing SseJ-OprF/I.
Effect of vaccination on tissue bacterial loads, postinfection serum cytokine
levels, and survival. A new immunization experiment was carried out using the
FIG 2 Antibody responses to immunization with Salmonella strains expressing Pseudomonas antigens.
Mice were inoculated intraperitoneally with plasmid-less S. Typhimurium aroA aroB (aro) or with the
same Salmonella strain carrying pWSK29 derivatives expressing PcrV or Opr fusion proteins as indicated.
Serum samples were collected from vaccinated and control mice 21 days after immunization and levels
of PcrV (A) or OprF/I (B) speciﬁc total IgG were measured by ELISA. Box and whisker plots represent the
interquartile ranges and ranges, respectively, and horizontal lines represent median values. ***, P 0.001
compared to levels in control mice using the Mann-Whitney U test.
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protective vaccine (attenuated Salmonella expressing SseJ-PcrV) or attenuated Salmo-
nella without a pWSK29 derivative as a control. Immunized and control mice were
challenged intraperitoneally with P. aeruginosa PAO1 21 days postimmunization. Twelve
hours after infection, spleen and lung bacterial loads were determined (Fig. 4A and B).
Vaccination with Salmonella expressing the SseJ-PcrV fusion dramatically reduced the
number of P. aeruginosa in spleens and lungs. To characterize the effect of immuniza-
tion on cytokine levels, sera were also collected 12 h after the infection with P.
aeruginosa, and the levels of tumor necrosis factor alpha (TNF-) and interleukin-6 (IL-6)
were determined (Fig. 4C and D). Levels of both cytokines were signiﬁcantly lower in
vaccinated mice than in control mice. Finally, the survival of vaccinated mice was
monitored for 7 days after challenge with P. aeruginosa (Fig. 4E). All mice vaccinated
with Salmonella expressing SseJ-PcrV were protected from challenge, whereas 6 of 7
mice inoculated with control Salmonella died in less than 48 h.
DISCUSSION
This study shows that the T3SSs of Salmonella can be used as vectors for efﬁcient
delivery of P. aeruginosa antigens and elicitation of protective immunity against this
opportunistic pathogen. In particular, the expression of a fusion between the Salmo-
nella effector SseJ and the Pseudomonas antigen PcrV under the control of PsseA
yielded successful results in the preclinical study shown here. Since PsseA responds to
intravacuolar signals and SseJ is a speciﬁc substrate of the T3SS2, the fusion protein
SseJ-PcrV is expected to be expressed by Salmonella inside the vacuole of the antigen-
presenting cell and translocated from the vacuole into the host cell cytosol. Previous
ﬁndings suggested that the translocation of fusion proteins results in major histocom-
patibility complex (MHC) class I- and MHC class II-restricted presentation and that a
fusion of the model antigen listeriolysin to SseJ induced T cell responses after vacci-
nation in mice (25). Here, we show that mice immunized with Salmonella expressing a
fusion of SseJ to PcrV, a relevant P. aeruginosa antigen, produced high levels of speciﬁc
anti-PcrV IgG and were able to survive an otherwise lethal infection with Pseudomonas.
Protection was observed in two independent experiments shown in Fig. 3 and Fig. 4E.
The differences in the results between these experiments could be due to multiple
factors that inﬂuence this kind of experiment (differences in the lots of mice that were
used, the exact state of the Salmonella cultures used for the vaccinations, different
Pseudomonas cultures used for challenge, reactions of individual mice to intraperitoneal
injections, etc.), but importantly, both experiments conﬁrmed that this vaccine con-
ferred statistically signiﬁcant protection against Pseudomonas. The protective effect of
this vaccination was conﬁrmed because immunized mice displayed lower bacterial
FIG 3 Survival curve of challenged mice. Groups of 8 C57BL/6 mice were intraperitoneally vaccinated
with an aroA aroB mutant of S. Typhimurium (aro) or with the same strain carrying the plasmids pIZ2160
or pIZ2267 for expression of the fusion proteins SseJ-OprF/I-FLAG (from the PsseA promoter) or
SseJ-PcrV-FLAG (from the PsseA promoter), respectively. Twenty-one days after the immunization, mice
were infected with P. aeruginosa strain PAO1 by intraperitoneal injection, and the survival of mice was
monitored for 7 days. Statistical signiﬁcance was determined by log rank analysis. *, P 0.05 compared
to levels in control mice inoculated with Salmonella aroA aroB.
A Live Salmonella Vaccine against Pseudomonas
March/April 2019 Volume 4 Issue 2 e00116-19 msphere.asm.org 5
 o
n
 April 22, 2019 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
loads in different organs and lower serum levels of proinﬂammatory cytokines. PcrV
was shown previously to induce protective immunity when delivered as a puriﬁed
recombinant protein antigen, alone or in combination with other antigens (16, 40–43).
In a recent report, mice were immunized intraperitoneally with recombinant PcrV
formulated with one of three different adjuvants (43). These vaccines were effective in
inducing speciﬁc immunity against PcrV and in conferring protection against a lethal
dose of P. aeruginosa.
FIG 4 Effect of vaccination on bacterial loads, postinfection proinﬂammatory cytokine levels, and survival. C57BL/6 mice were
intraperitoneally vaccinated with an aroA aroB mutant of S. Typhimurium (aro) or with the same strain carrying the plasmid pIZ2267 for
expression of the fusion protein SseJ-PcrV-FLAG from the PsseA promoter. Twenty-one days after the immunization, mice were infected
with P. aeruginosa strain PAO1 by intraperitoneal injection. Twelve hours postinfection, groups of 7 mice were euthanized to enumerate
the spleen (A) and lung (B) bacterial loads and to determine serum levels of TNF- (C) and IL-6 (D). Data points represent bacterial loads
or cytokine levels from individual mice, and horizontal lines represent median values from groups of mice. (E) Survival of other groups
of infected mice was monitored for 7 days. **, P 0.01; ***, P 0.001 compared to levels in control mice inoculated with Salmonella aroA
aroB. Differences in bacterial loads and cytokine levels were tested using the Mann-Whitney U test, and differences in survival were
analyzed by the log rank test.
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Surprisingly, a similar construct with the OprF/I antigen was unable to elicit the
production of speciﬁc antibodies or to provide protection against Pseudomonas. The
reasons for the superior immunogenicity of PcrV compared to that of OprF/I in our
system are unclear. The recombinant hybrid protein OprF(190-342)/OprI(21-83) was
shown to be immunogenic and protective in previous studies (13, 44). Glutathione
transferase (GST)-OprF/I elicited speciﬁc antibodies against P. aeruginosa and OprF
peptides and protected immunodeﬁcient mice against 975-fold the 50% lethal dose of
P. aeruginosa, whereas GST alone had no effect (45). A vaccine based on this hybrid
protein, IC43, was evaluated in a phase II clinical trial in mechanically ventilated
intensive care unit patients, although it did not produce signiﬁcant differences in
infection rates (11).
PcrV is an essential component of the T3SS. This system and its effectors are the
major virulence determinants of P. aeruginosa (46). Thus, the T3SS is an appealing
target for new therapies (47). PcrV, as part of the translocon, the most accessible part
of the T3SS, has been selected for targeting by antibodies developed for clinical use
(48). However, few vaccines have been described based on this antigen, presumably
because of solubility problems during puriﬁcation of the protein (41). The methodology
employed here circumvents these problems, since the antigen is produced by Salmo-
nella and directly translocated through the T3SS2 into the antigen-presenting cells. The
use of an in vivo inducible promoter, such as PsseA, instead of a constitutive promoter
is advantageous, because it enhances stable expression and immunogenicity of foreign
antigens expressed by Salmonella (49). The pWSK29 vector carries the pSC101 replicon
that produces 6 to 8 copies per cell (50) and is sufﬁciently stable for in vivo applications
(25).
The aim of this study was to characterize the ability of this vaccination approach to
produce an antibody response and to protect against infection in a preclinical model.
Although this is an important step toward the development of an effective vaccine for
the prevention of infections with P. aeruginosa, additional aspects could be optimized
in future experiments carried out in this model. (i) Tolerability and toxicity studies
would be necessary in order to advance this vaccine candidate. (ii) Other effectors could
be tested as carriers for the PcrV antigen, taking into account that the fusion with the
highest level of expression in vitro is not necessarily the most immunogenic in vivo (25).
(iii) Since Salmonella is also a pathogen, strains used to develop a live vaccine should
be attenuated. However, they should also be able to reach, multiply, and persist
temporarily in lymphoid organs to stimulate protective immune responses. Thus, a
balance between attenuation and immunogenicity is essential for the success of a live
vaccine. The aro mutants of S. Typhimurium used here are auxotrophic for aromatic
amino acids and several essential vitamins. These mutants are safe and immunogenic
in mouse models (51), where this serovar can reach systemic organs, and have
previously been used as carriers of heterologous antigens (52). Since S. Typhimurium
causes only self-limited intestinal disease in immunocompetent humans and does not
reach systemic sites in this host, the human-restricted S. enterica serovar Typhi is also
being tested as a live vector for humans (53). A double aro mutant of S. Typhi is highly
immunogenic, but additional attenuation could be desirable in humans; therefore,
other means of enhancing vaccine efﬁcacy and safety have been proposed (54). In
particular, the safety of live attenuated vaccines needs to be determined in immuno-
compromised individuals, since they represent a relevant target for vaccination against
Pseudomonas. In fact, an aro mutant may be virulent in immunodeﬁcient mice (55),
although moderate immunosuppression, causing increased susceptibility to wild-type
Salmonella, does not affect resistance to an aroA Salmonella vaccine strain (56). Other
attenuating mutations or combinations of mutations could be used to increase safety
(55). (iv) Another aspect to be considered for future development of this vaccine is the
route of immunization. The intraperitoneal injection is employed in many preclinical
studies but is not typically used in the clinical setting as a route of immunization.
However, mice can also be inoculated with Salmonella via the intravenous, subcuta-
neous, oral, intranasal, and rectal routes (57, 58), and some of these protocols should
A Live Salmonella Vaccine against Pseudomonas
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be tested in animal models before progressing into the clinical stages. It is also worth
noting that the cell-mediated immune response was not evaluated in this study, an
aspect that could be further characterized in future studies.
In conclusion, this study shows that the SPI2-related T3SS of Salmonella is an
appropriate vehicle to deliver the Pseudomonas antigen PcrV and to generate a
protective live vaccine against this opportunistic pathogen.
MATERIALS AND METHODS
Bacterial strains, bacteriophages, and strain construction. Bacterial strains used in this study are
described in Table 1. S. Typhimurium strains were derived from the wild-type strain ATCC 14028.
Transductional crosses using phage P22 HT 105/1 int201 (59) were used for strain construction (60).
Bacterial culture. The standard culture medium for all bacteria was Luria-Bertani (LB) broth. For
SPI2-inducing conditions, bacteria were inoculated in LPM at pH 5.8 (61) and incubated overnight at 37°C
with shaking. The following supplements were added to LPM to allow growth of aro strains: Phe,
40 g/ml; Trp, 40 g/ml; Tyr, 40 g/ml; p-aminobenzoate, 10 g/ml; 2,3-dihydroxybenzoate, 10 g/ml.
Solid medium contained 1.5% agar. Antibiotics were used at previously described concentrations (62).
DNA ampliﬁcation by PCR and sequencing. Ampliﬁcation reactions were carried out in a T100
thermal cycler (Bio-Rad) using KAPA HiFi DNA polymerase (Kapa Biosystems) or MyTaq Red DNA
polymerase (Bioline) according to the instructions of the suppliers. The oligonucleotides are described in
Table 2. Constructs were sequenced with an automated DNA sequencer (Stab Vida, Oeiras, Portugal).
Plasmids. The plasmids used in this study are listed in Table 1. The construction of derivatives of
pWSK29 for vaccine assays was carried out in three steps (Fig. 1): (i) cloning of P. aeruginosa DNA
fragments encoding antigens PcrV and OprF(190-342)/OprI(21-83) in fusion with FLAG using BamHI and
NotI restriction sites; (ii) addition of S. Typhimurium DNA encoding effector SseJ using EcoRI and BamHI
restriction sites; (iii) addition of PsseA using KpnI and EcoRI. The hybrid gene oprF-oprI was generated
using the gene splicing by overlap extension approach (63) as previously described (45) using oligonu-
cleotides shown in Table 2. To generate plasmid pIZ2338, the coding region of pcrV was ampliﬁed by
colony PCR using lysed P. aeruginosa PAO1 as the template and cloned into pGEX-4T-2 using BamHI and
EcoRI restriction sites. To generate plasmid pET15b-OprF/I, oprF-oprI was ﬁrst synthetized in vitro
(GenScript) and then transferred from the original vector (pUC57) into pET15b using NdeI and BamHI
restriction enzymes.
Expression and puriﬁcation of recombinant proteins in E. coli. Plasmids pET15b-OprF/I, express-
ing 6His-OprF/I, or pIZ2338, expressing GST-PcrV, were transformed into E. coli BL21(DE3). Bacteria
were grown in LB with ampicillin at 37°C. At mid-exponential-growth phase, 1 mM IPTG (isopropyl--D-
thiogalactopyranoside) was added to induce expression, and incubation was pursued for 4 h. The cells
were harvested by centrifugation, and the cell pellet was resuspended in NP-40 lysis buffer (64). A
commercial mixture of protease inhibitors (Sigma-Aldrich) was added to the suspension, and lysis was
performed by sonication. The cell lysate was centrifuged at 15,000  g for 30 min at 4°C, and the fusion
proteins were isolated from the supernatants by afﬁnity chromatography with Ni-nitrilotriacetic acid
TABLE 1 Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristics Source or reference
Strains
Escherichia coli
DH5 supE44 ΔlacU169 (80 lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 67
BL21(DE3) F- ompT gal dcm lon hsdSB(r m; E. coli B strain), with DE3,
a  prophage carrying the T7 RNA pol gene
Stratagene
Pseudomonas aeruginosa
PAO1 Reference strain 68
Salmonella enterica serovar
Typhimuriuma
14028 Wild type ATCC
SV4338 aroA551::Tn10 Laboratory stock
SV5136 ssaV::Cm Laboratory stock
SV8462 ΔaroB::Km Laboratory stock
SV9699 aroA551::Tn10 ΔaroB::Km This work
Plasmids
pET15b 6His fusion vector, Apr Novagen
pET15b-OprF/I OprF/I cloned with NdeI and BamHI This work
pGEX-4T-2 GST fusion vector, Apr GE Healthcare
pIZ2160 pWSK29-PsseA-SseJ-OprF/I-FLAG This work
pIZ2267 pWSK29-PsseA-SseJ-PcrV-FLAG This work
pIZ2338 pGEX-4T-2-PcrV This work
pWSK29 Low-copy-number vector, Apr 50
aDerivatives of these strains were used as indicated in the text.
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(NTA) agarose beads (Qiagen) or glutathione agarose beads (Sigma-Aldrich) according to the manufac-
turers’ protocols.
Mammalian cell culture. RAW264.7 cells (murine macrophages, ECACC number 91062702) were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% fetal calf serum and
2 mM L-glutamine. Penicillin (60 g/ml) and streptomycin (100 g/ml) were included in the culture
medium (except for bacterial infection experiments). Cells were maintained in a 5% CO2 humidiﬁed
atmosphere at 37°C.
Bacterial infection of cultured cells and protein translocation assays. RAW264.7 cells were plated
24 h before infection in 6-well plates at 8 105 cells per well and incubated 24 h at 37°C with 5% CO2
in medium without antibiotics. Bacteria carrying plasmids expressing FLAG fusions were grown in LB
medium with ampicillin for 24 h at 37°C with shaking, were added to the cell monolayers at a multiplicity
of infection of 250 bacteria/cell, and then were incubated at 37°C with 5% CO2. The cell culture was
washed twice with phosphate-buffered saline (PBS) 1 h postinfection, overlaid with DMEM containing
100 g/ml gentamicin and ampicillin, and incubated for 1 h. The culture was then washed twice with
PBS, covered with DMEM with gentamicin (16 g/ml) and ampicillin (100 g/ml), and incubated for 6 h.
To study the translocation of FLAG fusions, infected mammalian cells were lysed with 1% Triton X-100.
Cell lysates were processed for electrophoresis and Western blotting as previously described (65).
Anti-DnaK (1:5,000; Assay Designs) and anti-GroEL (1:20,000; Sigma-Aldrich) antibodies were used as
loading or contamination controls.
Analysis of expression of fusion proteins. Salmonella strains carrying plasmids expressing FLAG
fusions were grown overnight in LB medium at 37°C with shaking. Bacteria were then washed, diluted
1:50 in LPM, and incubated at 37°C with shaking for 8 h. The bacteria were then pelleted by centrifu-
gation and lysed by boiling in Laemmli sample buffer. Proteins were separated by SDS-PAGE and
analyzed by immunoblotting with a monoclonal antibody directed to the FLAG epitope (1:10,000;
Sigma-Aldrich). Goat anti-mouse horseradish peroxidase (HRP)-conjugated antibody (1:5,000; Bio-Rad)
was used as the secondary antibody.
Mouse immunization and infection with P. aeruginosa. Mice were maintained in the IBiS facility,
and their care was in accordance with institutional guidelines. Attenuated S. Typhimurium strain SV9699
(aroA551::Tn10 ΔaroB::Km) (Table 1) with appropriate plasmids was grown overnight at 37°C with shaking
in LB with ampicillin, diluted in fresh medium (1:100), and grown to an optical density at 600 nm (OD600)
of 0.3 to 0.6. Vaccination was carried out in 6- to 8-week-old female C57BL/6 mice (Charles River
Laboratories) by a single intraperitoneal injection with 0.2 ml of PBS containing 2 105 CFU of Salmo-
nella. Mice were infected with P. aeruginosa strain PAO1 on day 21 postimmunization by intraperitoneal
injection with 9 106 bacteria (3.6 the 50% lethal dose [LD50]) in 0.2 ml of PBS, and survival was
monitored for 7 days. Mice that received the same infection were housed together with up to 5 mice per
cage. Mice were monitored twice daily and culled using thiopental at the end of the experiments. The
procedures (intraperitoneal injections) made the use of analgesics unnecessary. To minimize animal
suffering, euthanasia using thiopental was carried out immediately when detecting severe clinical signs:
hunching, labored breathing, severe weight loss, inactivity, or lethargy. Experiments involving the use of
animals were approved by the Committee on Ethics and Experimentation of the Consejería de Agricul-
tura, Pesca y Desarrollo Rural (Junta de Andalucía, Spain) (permit number 18-01-16-005) and were in
accordance with the EU Directive 2010/63/EU for animal experiments.
Spleen and lung bacterial loads and serum cytokine levels. Postinfection bacterial loads were
determined in vaccinated and control mice 12 h after infection. Mice were euthanized with thiopental,
TABLE 2 Oligonucleotides used in this study
Oligonucleotide Sequence 5=¡3=
Ampliﬁcation of pcrV with FLAG tag for cloning in pWSK29
pcrVfwBam ATCGGGATCCGAAGTCAGAAACCTTAATGC
pcrVFLAGrevNot GCATGCGGCCGCCTATTTATCGTCGTCATCTTTGTAGTCGATCGCGCTGAGAATGTCGC
Fusion of oprF and oprI with FLAG tag
oprFfwBam ATCGGGATCCGCTCCGGCTCCGGAACCGGTTGCCGAC
oprFrev TTCAACGCGACGGTTGATAGCGCG
oprF/oprIfw GAAGGCCGCGCTATCAACCGTCGCGTTGAAAGCAGCCACTCCAAAGAAAC CGAAGCT
oprIFLAGrevNot GCATGCGGCCGCCTATTTATCGTCGTCATCTTTGTAGTCCTTGCGGCTGGCTTTTTCCAG
Ampliﬁcation of sseJ
sseJfwEco CCTAGAATTCGTAAGGAGGACACTATGCC
sseJrevBam ACGTGGATCCTTCAGTGGAATAATGATGAG
Ampliﬁcation of sseA promoter
PsseAfwKpn GCTAGGTACCAGAAGAGAACAACGGCAAG
PsseArevEco CACTGAATTCACGATAGATAATTAACGTGC
Ampliﬁcation of pcrV for cloning in pGEX-4T-2
pcrVfwBam ATCGGGATCCGAAGTCAGAAACCTTAATGC
pcrVrevEco ATCGGAATTCCTAGATCGCGCTGAGAATGT
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and after the collection of blood samples from the retro-orbital sinus, spleens and lungs were aseptically
removed, weighed, and homogenized in 2 ml of physiological saline. Serial log dilutions were plated on
agar plates for bacterial quantiﬁcation. Serum levels of tumor necrosis factor alpha (TNF-) and
interleukin-6 (IL-6) were determined in mice at 12 h postinfection using DuoSet ELISA kits (R&D Systems).
Enzyme-linked immunosorbent assays. For indirect ELISAs, 96-well plates were coated with 100 l
per well of 1-g/ml solutions of puriﬁed 6His-OprF/I or GST-PcrV by incubating at 4°C overnight. ELISAs
were performed using sera collected on day 21 as described previously (66). Antibody titers were
measured against the OprF/I or PcrV antigens and were deﬁned as the dilution in which spectrophoto-
metric readings were at least 0.1 units greater than that in the background wells (wells containing no
serum).
Statistical analysis. Antibody titers, bacterial loads, and cytokine levels were compared using the
Mann-Whitney U test. Survival data were compared using the log rank test. Statistics were performed
using SPSS version 24.0 software (SPSS Inc.). P values of 0.05 or less were considered signiﬁcant.
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